Tweet
Sci Rep
. 2022 Jun 20;12(1):10359.
doi: 10.1038/s41598-022-13560-z.
Intranasal vaccination of hamsters with a Newcastle disease virus vector expressing the S1 subunit protects animals against SARS-CoV-2 disease
Manolo Fernández Díaz 1 , Katherine Calderón 2 , Aldo Rojas-Neyra 2 , Vikram N Vakharia 3 , Ricardo Choque-Guevara 2 , Angela Montalvan-Avalos 2 , Astrid Poma-Acevedo 2 , Dora Rios-Matos 2 , Andres Agurto-Arteaga 2 , Maria de Grecia Cauti-Mendoza 2 , Norma Perez-Martinez 2 , Gisela Isasi-Rivas 2 , Luis Tataje-Lavanda 2 , Yacory Sernaque-Aguilar 2 , Freddy Ygnacio 2 , Manuel Criollo-Orozco 2 , Edison Huaccachi-Gonzalez 2 , Elmer Delgado-Ccancce 2 , Doris Villanueva-Pérez 2 , Ricardo Montesinos-Millán 2 , Kristel Gutiérrez-Manchay 2 , Katherinne Pauyac-Antezana 2 , Ingrid Ramirez-Ortiz 2 , Stefany Quiñones-Garcia 2 , Yudith Cauna-Orocollo 2 , Katherine Vallejos-Sánchez 2 , Angela Rios-Angulo 2 , Dennis Núñez-Fernández 2 , Mario I Salguedo-Bohorquez 2 , Julio Ticona 2 , Manolo Fernández-Sánchez 2 , Eliana Icochea 2 , Luis A Guevara-Sarmiento 2 , Mirko Zimic 4 , COVID-19 Working Group in Perú
Collaborators, Affiliations
- PMID: 35725862
- DOI: 10.1038/s41598-022-13560-z
Abstract
The coronavirus disease-19 (COVID-19) pandemic has already claimed millions of lives and remains one of the major catastrophes in the recorded history. While mitigation and control strategies provide short term solutions, vaccines play critical roles in long term control of the disease. Recent emergence of potentially vaccine-resistant and novel variants necessitated testing and deployment of novel technologies that are safe, effective, stable, easy to administer, and inexpensive to produce. Here we developed three recombinant Newcastle disease virus (rNDV) vectored vaccines and assessed their immunogenicity, safety, and protective efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in mice and hamsters. Intranasal administration of rNDV-based vaccine candidates elicited high levels of neutralizing antibodies. Importantly, the nasally administrated vaccine prevented lung damage, and significantly reduced viral load in the respiratory tract of vaccinated animal which was compounded by profound humoral immune responses. Taken together, the presented NDV-based vaccine candidates fully protected animals against SARS-CoV-2 challenge and warrants evaluation in a Phase I human clinical trial as a promising tool in the fight against COVID-19.